<DOC>
	<DOCNO>NCT01910259</DOCNO>
	<brief_summary>Multiple sclerosis ( MS ) disable progressive neurological disease affect approximately 100,000 people UK . Many patient MS experience two phase disease ; early MS ( also call relapse remit MS , RRMS ) late MS ( also call secondary progressive MS ( SPMS ) . Early MS due inflammation nerve insulation ( call myelin ) surround nerve . Early MS often characterise period `` attack '' intersperse period `` remission '' low disease symptom . Late progressive MS , affect majority patient typically emerge 10-15 year disease , result actual nerve death ( also call neurodegeneration ) . The progressive stage disease result individual attack slow , cumulative irreversible disability affect walking , balance , vision , cognition , pain control , bladder bowel function . Critically , unlike early disease , proven treatment late stage MS . This therefore urgent major unmet health need . MS-SMART directly address need evaluate clinical trial three drug ( fluoxetine , riluzole amiloride ) , show promise MS , particular SPMS . The trial randomise blind . Randomisation mean patient get one three active drug inactive placebo/dummy ; blind mean neither patient doctor know drug placebo patient receive . Randomisation blind standard approach clinical trial ensure unbiased test drug . All patient MS-SMART periodic MRI ( magnetic resonance imaging ) brain scan 96 week analyse . We compare scans drug placebo dummy see drug slow rate brain shrinkage normally occur SPMS . This measured change brain size primary ( major ) outcome MS-SMART .</brief_summary>
	<brief_title>MS-SMART : Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial</brief_title>
	<detailed_description>MS-SMART test efficacy mechanism action three repurposed drug ( fluoxetine , riluzole amiloride ) . All three drug human use good safety record . Critically purpose MS-SMART show promise early phase human MS clinical trial target one pivotal neurodegenerative causing pathway implicate SPMS . This Type B trial , IMPs human use , good safety profile currently use patient population . The major need patient establish progressive MS neuroprotective disease modify treatment slow even stop disease progression . This study evaluate three highly promise putative neuroprotective drug well comprehensively address several current knowledge gap relate understanding neuroprotection neurodegeneration SPMS MRI CSF examination . MS-SMART multicentre , multi-arm , double blind , placebo-controlled phase IIb randomise control trial . A total 440 patient SPMS , entry criterion EDSS score 4.0-6.5 equally randomised receive placebo one three active agent ( fluoxetine 20mgbd , amiloride 5mg bd riluzole 50mg bd ) . Patients follow 96 week outcome-data collect 0 , 24 , 48 96 week . That , duration trial trial participant 96 week ( telephone assessment week 100 , 4 week post completion conduct ) . This standard practice phase II trial SPMS .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<mesh_term>Amiloride</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<criteria>Confirmed diagnosis SPMS . Steady progression rather relapse must major cause increase disability precede 2 year . Evidence progression , either increase least one point EDSS clinical documentation increase disability patient note Expanded Disability Status Scale ( EDSS ) 4.06.5 Aged 25 65 inclusive Women men partner childbearing potential must use appropriate method contraception avoid unlikely teratogenic effect 3 drug time consent , 6 week treatment inclusive Women must negative pregnancy test within 7 day prior baseline visit unless child bear potential ( e.g . undergone hysterectomy , bilateral tubal ligation bilateral oophorectomy postmenopausal ) Willing able comply trial protocol ( e.g . tolerate MRI fulfils requirement MRI , e.g . fit pacemaker permanent hear aid ) , ability understand complete questionnaire Written inform consent provide Pregnancy breast feed patient Baseline MRI scan adequate quality analysis ( e.g . much movement artefact ) Significant organ comorbidity ( e.g . malignancy renal hepatic failure ) Relapse within 3 month baseline visit Patients treat iv oral steroid MS relapse/progression within 3 month baseline visit ( patient undergo future screen visit 3 month window expire ) , patient steroids another medical condition may enter long steroid prescription multiple sclerosis ( relapse/ progression ) . Use Simvastatin 80mg dose within 3 month baseline visit ( low dose Simvastatin statin permissible ) Commencement fampridine within 6 month baseline visit Use immunosuppressant ( e.g . azathioprine , methotrexate , cyclosporine ) disease modify treatment ( βinterferons , glatiramer ) within 6 month baseline visit Use fingolimod/fumarate/teriflunomide/laquinomod/or experimental disease modify treatment ( include research investigational medicinal product ) within 12 month baseline visit Use mitoxantrone/ natalizumab/ alemtuzumab/ daclizumab treat within 12 month baseline visit Primary progressive MS Relapsingremitting MS Known hypersensitivity active substance excipients active drug trial Use : lithium , chlorpropamide , triamterene spironolactone within 6 month baseline visit Current use potassium supplement Current use tamoxifen Current use herbal treatment contain St. John 's Wort Significant sign depression Use SSRI within 6 month baseline visit Use monoamine oxidase inhibitor , phenytoin , Ltryptophan ) and/or neuroleptic drug within 6 month baseline visit A Beck Depression Index score 19 high Bipolar disorder Receiving previously receive ElectroConvulsive Therapy Epilepsy/seizures Glaucoma Patients history bleed disorder currently anticoagulant Routine screen blood value ( LFT ) &gt; / 3 x upper limit normal ( ULN ) site reference range ( ALT/AST , bilirubin , ˠGT ) Potassium &lt; 2.8mmol/l &gt; 5.5mmol/l Sodium &lt; 125mmol/l Creatinine &gt; 130μmol/l WBCs &lt; 3 x 109/l Lymphocytes &lt; 0.8 x 109/l Neutrophil count &lt; 1.0 x 109 /l Platelet count &lt; 90 x 109 /l Haemoglobin &lt; 80g/l</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Secondary Progressive Multiple Sclerosis</keyword>
	<keyword>Neuroprotective</keyword>
	<keyword>Repurposed drug</keyword>
	<keyword>Brain atrophy</keyword>
	<keyword>Percentage Brain Volume Change</keyword>
	<keyword>Magnetic Resonance Imaging</keyword>
	<keyword>Optical Coherence Tomography</keyword>
	<keyword>Cerebrospinal fluid</keyword>
	<keyword>Ibudilast</keyword>
	<keyword>Amiloride</keyword>
	<keyword>Riluzole</keyword>
	<keyword>Double blind</keyword>
	<keyword>Placebo</keyword>
</DOC>